Janone charts ambitious strategic course for non-addictive pain management

In meetings hosted by nasdaq marketsite , the company reviewed its drug development programs that fight the opioid crisis through pharmaceuticals that reduce pain without causing addiction. las vegas , jan. 26, 2023 /prnewswire/ -- janone (nasdaq: jan), which develops treatments for underlying causes of severe pain and brings to market drugs that relieve pain without the risk of addiction, held meetings at new york's nasdaq marketsite to review strategic plans and to facilitate integration of recently-acquired soin therapeutics.
JAN Ratings Summary
JAN Quant Ranking